Design
Review
Authors
Loading...
Does not support MR antagonist use in obese patients yet; leaves open whether targeting this pathway improves cardiometabolic outcomes.
Key points are not available for this paper at this time.
Even et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: